The present invention relates to compounds and pharmaceutically acceptable
salts of formula (I): ##STR00001## which are useful in the treatment of
metabolic disorders related to insulin resistance or hyperglycemia. These
compounds include inhibitors of protein tyrosine phosphatase (PTP-1B)
that are useful in the treatment of diabetes and other PTP-1B mediated
diseases, such as cancer, neurodegenerative diseases and the like. The
compounds of the invention are also useful in pharmaceutical compositions
and methods of treating the aforementioned conditions.